Details

Bleomycin electrosclerotherapy (BEST) : mechanistic parallels to electrochemotherapy, experimental models, and unresolved questions
ID Lisec, Barbara (Author), ID Čemažar, Maja (Author), ID Muir, Tobian (Author), ID Omerzel, Maša (Author), ID Jesenko, Tanja (Author), ID Markelc, Boštjan (Author), ID Grošelj, Aleš (Author), ID Dežman, Rok (Author), ID Štabuc, Miha (Author), ID Kuhelj, Dimitrij (Author), ID Serša, Gregor (Author)

.pdfPDF - Presentation file, Download (2,26 MB)
MD5: C2E86E8FD336E838C5F05933CE0E95A8
URLURL - Source URL, Visit http://dx.doi.org/10.2478/raon-2026-0017 This link opens in a new window

Abstract
Background. Bleomycin electrosclerotherapy (BEST) is an emerging treatment option for vascular malformations (VMs), predominantly slow-flow venous malformations, with increasing use in other types of VMs. By combining application of bleomycin with electroporation, BEST enhances intracellular drug delivery and may improve treatment efficacy while allowing the use of lower drug doses. Although clinical evidence supporting its efficacy is growing, the biological mechanisms underlying these effects remain poorly understood. Key unresolved questions include endothelial responses to BEST, what are the dominant mechanisms of vascular injury and remodeling, and how hemodynamics and abnormal vessel architecture affect bleomycin distribution, pharmacokinetics, and effective dosing within the lesion. Although the clinical effects of BEST may be similar to the vascular disrupting effect of electrochemotherapy, it remains unclear whether these vascular mechanisms are in fact the same. Conclusions. Understanding, how bleomycin is delivered, distributed, and retained within VM tissue, and how this interacts with endothelial susceptibility and electroporation efficiency, will be essential for defining optimal dosing strategies. Addressing these questions will require experimental approaches and physiologically relevant models capable of capturing the genetic, structural, and hemodynamic features of VMs. Such advances will be critical for elucidating the mechanisms of BEST and optimizing its clinical application.

Language:English
Keywords:vascular malformations, bleomycin electrosclerotherapy, BEST, electrochemotherapy
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2026
Number of pages:14 str.
Numbering:Vol. 60, iss. 1
PID:20.500.12556/RUL-181360 This link opens in a new window
UDC:616-006
ISSN on article:1581-3207
DOI:10.2478/raon-2026-0017 This link opens in a new window
COBISS.SI-ID:271953155 This link opens in a new window
Publication date in RUL:03.04.2026
Views:82
Downloads:22
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Radiology and oncology
Publisher:Association of Radiology and Oncology
ISSN:1581-3207
COBISS.SI-ID:784507 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:Institut of Oncology Ljubljana
Project number:OI-8-24

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back